AMPE — Ampio Pharmaceuticals Share News
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Brief: Ampio Announces Early Positive Data In Phase 1 Trial Of Inhaled Ampion In COVID-19 Respiratory Distress
Brief: Ampio Pharmaceuticals Ongoing Phase I Clinical Trial For Inhalation Treatment Of Covid-19 With Ampion Is 55% Enrolled
Brief: Ampio Provides Update On Clinical Trials For Ampion Treatment Of Covid-19 Patients
Brief: Ampio Receives Feedback From FDA On Ampio's Proposed Modifications To Special Protocol Assessment For Ampion Treatment Of Severe Osteoarthritis Of Knee
Brief: Ampion Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion
Brief: Ampio Enters Into Collaborative Research Agreements
Ampio Pharma: Up after COVID-19 drug study advances to full enrollment
Brief: Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress
Brief: Ampio Pharmaceuticals Inc - FDA Notified Co That Formal Response On Oak Phase 3 Clinical Trial Will Be Provided By End Of This Year
Brief: Ampio's Phase I Study For Inhaled Ampion Advances To 3rd Group Of Covid-19 Patients With Respiratory Distress
Brief: Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of Covid-19 Patients
Brief: Ampio Begins Phase 1 Clinical Trial Of Inhaled Ampion For Covid-19 Patients With Respiratory Distress
Brief: Ampio Publication Reports Beneficial Effects Of Ampion On Important Transcription Factors In Inflammation
Ampio soars on FDA nod to study lead drug as COVID-19 respiratory distress therapy
Brief: FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients
Ampio rises after positive data on IV treatment for COVID-19
Brief: Ampio Reports Positive Results For Ampion Treatment In Covid-19 Patients
Brief: Ampio Announces Enrollment Completion For Intravenous COVID-19 Clinical Trial
Brief: Ampio Pharma Says Securities Class Action, Cetrone Action And Theise Action Have Been Dismissed - SEC Filing